Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Momelotinib (MMB)	8	104
Total, all-cause mortality	Best Available Therapy (BAT)	5	52
Total, all-cause mortality	MMB to MMB	29	64
Total, all-cause mortality	BAT to MMB	18	40
Total, other adverse events	Momelotinib (MMB)	99	104
Total, other adverse events	Best Available Therapy (BAT)	46	52
Total, other adverse events	MMB to MMB	63	64
Total, other adverse events	BAT to MMB	40	40
Total, serious adverse events	Momelotinib (MMB)	37	104
Total, serious adverse events	Best Available Therapy (BAT)	12	52
Total, serious adverse events	MMB to MMB	33	64
Total, serious adverse events	BAT to MMB	19	40

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02101268/event-totals